Myeloid Sarcoma: The Other Side of Acute Leukemia by Kahali, Bhaskar
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
Chapter 6
Myeloid Sarcoma: The Other Side of Acute Leukemia
Bhaskar Kahali
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/intechopen.74931
Abstract
Myeloid sarcomas are extramedullary myeloid masses with associated tissue damage.
Myeloid sarcomas usually arise before, during or after diagnosis of acute leukemia, most
often AML. Majority of the patients with myeloid sarcoma respond to upfront systemic
chemotherapy and sometimes bone marrow transplant, but it is unclear which patients
will benefit from which treatments. This is primarily due to the paucity of knowledge on
myeloid sarcoma. At present, there are no prognostic biomarkers for myeloid sarcoma,
which can help in risk stratification in patients with myeloid sarcoma. Several studies
have suggested that myeloid sarcoma is more likely to occur with certain translocations
such as CBF and MLL rearrangements. In addition, sequencing analysis has identified
several mutations in genes such as FLT3, NPM1, EZH2, and KIT. Nevertheless, there is
still lack of knowledge to understand why particular leukemia migrates to the skin and
soft tissues and becomes refractory to systemic therapy.
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1. Introduction
Myeloid Sarcoma (MS) constitutes a rare pathological condition of extramedullary manifesta-
tion of leukemic cells of primarily myeloid origins that destroy the normal tissue architecture
at the site of origin. Presence of the enzyme myeloperoxidase (MPO), gives the tumors its
characteristic green hue, leading to the term, ‘chloroma’ (Greek, Chloros, meaning green)
coined by a British physician, A. Burns in 1811 [1, 2]. Alternatively, MS is also referred as,
Granulocytic sarcoma or Myeloblastoma. In the majority of the cases, MS is associated with
acute myeloid leukemia (AML), however, it may also manifest in non-leukemic individuals. In
addition, MS has also been reported in cases of myeloproliferative neoplasms (MPN), or
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myelodysplastic disorders (MPD) [3, 4]. At present, MS represents a major subgroup of mye-
loid neoplasms and acute leukemia in WHO classification [5].
2. Epidemiology
MS can manifest under different clinical scenarios including, (1) MS with concurrent AML, (2)
as an isolated tumor and may precede the blood and bone marrow involvement or without
any history of myeloid neoplasia and, (3) extramedullary relapse of AML [1, 3, 6–9]. However,
with a limited number of prospective studies, the exact frequency and the extent of MS are not
well described. Based on the retrospective and the autopsy studies, the occurrence of MS in
AML patients is reported to be 10% across genders and all age groups [3, 10, 11]. In depth
analysis however revealed that MS primarily affects pediatric patients (>50% of all MS
patients) with slight male biasness [7, 12, 13]. In 15–35% of cases, MS can appear concomitantly
with AML, whereas, in 50% of cases MS appears following the diagnosis of AML. In rare
instances (<1%), MS has also been diagnosed after allogenic stem cell transplantation (allo-
SCT), which manifests as an isolated tumor with or without accompanying blood and bone
marrow relapse [14, 15].
3. Mechanisms
The precise mechanism underlying the development of MS is unclear. However, extra-
medullary infiltration by acute leukemia strongly implicates the presence of an alternative
homing signal that enables the blast cells to re-localize to these secondary sites. In this context,
strong evidence was provided by the studies demonstrating the presence of different chemo-
kine receptors on blast cells in MS and concurrent AML involving blood and bone marrow
[16]. Taken together, these observations led to the proposal that unusual manifestations of
adhesion molecules dictate the migration of AML subclones to surrounding tissues.
Stefanidakis et al. provided further insights into the migratory capacity of blast cells. In their
study, the authors reported that a major factor for the migration of AML cells into non-myeloid
regions is the interactions between matrix metalloproteinase (MMP) – 9 and leukocyte β2
integrin along with some unidentified proteins [2]. Stefanidakis et al. termed the complex,
‘invadosome’ [2]. The observations that highly invasive AML cell lines express high level of
MMP-2 and tissue inhibitor of metalloproteinase 2 (TIMP2) further support the conclusion of
Stefanidakis and colleagues [17]. In a recent study, Zhu et al. has reported a correlation
between high expression of enhancer of Zeste 2 (EZH2), the catalytic subunit of polycomb
repressor complex 2 (PRC2), and extramedullary infiltration of AML [18]. The authors have
indicated that increased expression of EZH2 attenuates the expression of TIMPs, which result
in the upregulation of MMPs. The uninhibited MMPs ultimately degrades the extracellular
matrix (ECM) and thus aid in the escape of the blast cells in the extramedullary space [18].
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4. Sites of involvement and symptoms
MS can manifest in different anatomical sites. However, there is a lack of study to establish a
correlation between AML and predilection for sites by MS. The most commonly involved sites
of MS are skin, bone and lymph nodes [3, 10, 11]. In addition, other sites associated with MS
include central nervous system (CNS), oral and nasal mucosa, breasts, genitourinary tract,
chest wall, testis etc. Skin is the primary sites for the development of MS in pediatric patients
(54%), followed by ocular region [3, 10, 11].
In majority of instances, MS is asymptomatic. Even so, depending on the size and location of
the tumor, the most common signs and symptoms associated with MS are compression
accompanied by pains, bleeding, fever and fatigues [1].
5. Diagnosis and disease pathology
At present, there is no specific diagnosis for MS. Given the fact that MS in majority of cases is
asymptomatic and does not elicit any specific symptoms, it often poses serious diagnostic
challenge for a clinician. Consequently, MS is often misdiagnosed as large cell lymphoma,
malignant melanoma, extramedullary hematopoiesis or inflammation. However, diagnosis of
MS in association with existing leukemia is comparatively easier than isolated MS. Detection
and identification of MS requires the coordinated intervention of different medical procedure.
Computed tomography (CT) and magnetic resonance imagery (MRI) are generally used for
the detection of the tumors [19]. Following the detection of tumors biopsies are conducted to
confirm the malignancy of the mass.
However, accurate diagnosis of MS requires histological examination and immunophenotypic
analysis. Histological analysis of MS generally elicits myeloid cells at different stages of matu-
ration. The infiltrating leukemic cells generally elicit irregular large nuclei and large
cytoplasm-to-nuclear ratio. Depending on the predominant cell types in the tumors, MS are
classified into granulocytic, monoblastic and myelomonocytic. In addition, depending on the
maturity of the cells, MS are further subdivided into immature, mature and blastic types [11].
In addition to morphology, cytochemical stainings on imprints may allow for confirming the
myeloid affiliation and differentiating granulocytic-lineage and monoblastic forms. According
to the WHO 2016 classification, cytochemical stains may include myeloperoxidase and naph-
thol AS-D chloroacetate esterase (positive in granulocytic MS), as well as non-specific esterase
(positive in monoblastic MS) [5]. The diagnosis is further validated by immunophenotyping.
Flow cytometric analysis on cell suspensions can be performed; however, immunohistochem-
istry on paraffin-embedded tissue sections is more commonly used for the detection of lineage
affiliation and evaluation of maturation. MS are usually positive for myeloid and monocytic
markers, i.e. CD33, CD68, lysozyme, the more immature markers such as CD117 and CD34,
CD61, glycophorin, CD4, etc. CD99 and TdT may also be positive. CD56 can be detected in
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around 20% of MS cases [1, 12]. NPM1 cytoplasmic and nuclear staining indicates NPM1 gene
mutations. To exclude the possibility of lymphoma the tumors should be interrogated for
different T and B lineage markers such as, CD3, CD20, and CD79a. Aberrant expression of
B/T-cell markers is possible, however, if criteria for a mixed-lineage leukemia are fulfilled the
case is not classified as MS according to WHO 2016. Particular antigenic constellations may
more precisely define subtypes shown in Table 1.
MS is also associated with several cytogenetic and chromosomal abnormalities (please see next
section for detailed report). Consequently, fluorescence in situ hybridization (FISH) should be
employed as a part diagnostic work up for patient stratification [20].
6. Cytogenetics and molecular genetics of myeloid sarcoma
Cytogenetic analysis conducted with bone marrow and peripheral blood blasts in MS patients
has demonstrated cytogenetic abnormalities in more than 50% of instances [21]. Nonetheless,
the rates of specific cytogenetic abnormalities associated with MS are rather diverse. Studies
have elicited the frequent association of between MS and core binding factor (CBF) leukemia
and AML with MLL rearrangements [22]. The most common chromosomal abnormality,
t(8;21), is associated with pediatric MS or in patients with ocular involvement [21, 23, 24]. The
second predominant chromosomal aberration associated with pediatric MS is inv16 [3, 25].
However, studies by Pileri et al. showed the relative rarity of t(8,21) in adult MS patients [21].
Instead, trisomy 8, monosomy 7 and MLL rearrangements constitute the majority of the cases
[21]. The prevalence of inv16 was also not well documented in adult patients. In addition,
other chromosomal aberrations including monosomy 5, 7 or 8 were reported in isolated cases.
Nucleophosmin (NPM)-1 mutations have been reported to be in 15% of MS patients. This
particular variant of MS elicits clinical attributes similar to NPM-1 positive AML and manifest
primarily in M4 and M5 French American British (FAB) subclasses of AML [26]. NPM-1
Immunophenotypic
profiles
Most common markers
Myeloid Myeloperoxidase (MPO), CD33, CD68 (detected by KP1 monoclonal antibody but not by
PG-M1), CD34, CD117
Promyelocytic Myeloperoxidase (MPO), CD15, CD117, lacking CD34 and TdT
Myelomonocytic Homogeneous expression of CD68 (KP1), while CD68 (PG-M1) and MPO in distinct
subpopulations
Monoblastic CD68 (PG-M1), CD14, lacking MPO, CD163, CD11c
Megakaryoblastic CD61, von Willebrand factor
Erythroid CD71, glycophorin A, glycophorin C
Table 1. Common immunophenotypes.
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mutant positive MS is also associated with the loss of CD34 expression and normal karyotype.
Studies conducted by Ansari-Lari et al. have reported the presence of FLT3-ITD mutation in
33% (three of nine) of MS patients with concurrent AML [27]. However, the implications of
NPM-1 and FLT3-ITD mutations on prognosis of MS are still not clear and data are too scarce
for definite conclusions. In their retrospective study, Vega-Ruiz et al. showed that 3% of
patients with acute promyelocytic leukemia (APL) manifest MS, predominantly in CNS [28].
Studies conducted by several groups have also attributed the development of MS to the use of
all-trans retinoic acid (ATRA) or with conventional chemotherapy [29].
7. Imaging as a diagnostic tool
Timely identification of MS has a significant impact on the treatment outcomes and achieving
remission in case of AML. As often, these extramedullary tumors serve as sanctuary sites for
future relapse. However, detection and simultaneous identification of MS is challenging. The
standard AML diagnosis does not include MS, nor there are any specific diagnostic regimens
for MS. Consequently, in majority of cases diagnosis of MS is either significantly delayed or
remain undetected. In this context, multimodal imaging procedure can be beneficial for early
detection of tumors [30]. This generally involves employment of traditional imaging tech-
niques such as, positron emission tomography (PET), CT and MRI [25]. Particularly, in the last
decades, PET/CT is becoming an essential tool for disease detection [25]. In this context, 18F-
fluorodeoxygenase (18F-FDG)PET/CT has been recognized as a very potent instrument for the
identification of not only leukemia but also extramedullary invasion of blast cells [8, 31, 32]. In
a prospective study, Stölzel et al. have successfully employed whole-body 18F-FDG PET/CT in
94 AML patients, consisting of both newly diagnosed and relapsed cases of AML for detection
of MS [33]. In a different study, Aschoff et al. have demonstrated the sensitivity of 18F-FDG
PET/CT by reducing the number of false-positive associated with traditional PET imaging [34].
In addition, 18F-FDG PET/CT has also been able identify new sites of MS, which is not
identified by traditional imaging techniques [8].
Although, encouraging, 18F-FDG PET/CT does have some restrictions. Several reports have
shown that 18F-FDG PET/CT is not sensitive enough to pick up extramedullary infiltration in
the soft tissues such as skin meninges and mucus membranes. In addition, 18F-FDG is not a
tumor specific marker but rather depends on the glucose uptake by the cells [8]. As such, there
is an increase chance of false-positive signals associated with 18F-FDG PET/CT specifically, in
brain and kidney that have high basal glucose metabolism [9]. As an alternative, various
groups have used 18F-fluorodeoxythymidine (FLT), a thymidine analogue and proliferating
marker, as a tracer for PET/CT in place of 18F-FDG [8]. Unlike 18F-FDG, 18F-FLT has generally
low uptake in different organs, such as brain and kidney and therefore elicits comparatively
less background [35]. Although, as of now there has been no prospective/retrospective study
with 18F-FLT PET/CT for MS detection, but the sensitivity and accuracy of 18F-FLT PET/CT
has been demonstrated in different cancers including, non-small cell lung cancer (NSCLC) and
NPM-ALK-Positive lymphoma [8, 36].
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8. Treatment
Given the scarcity of positively diagnosed MS and randomized prospective trials, there is at
present no consensus MS specific therapeutic regimen. The current routine includes conven-
tional AML-type chemotherapy and radiotherapy for both isolated and MS or MS with con-
comitant AML. Studies led by different groups have shown that standard AML therapy
exhibits better overall survival in case of isolated MS incidents [10]. Nevertheless, there is a
lack of data addressing a particular chemotherapeutic regimen for MS. Existing data indicates
cytarabine to be an essential drug in this regard [37].
The use of radiotherapy is also not well studied as a prospective means of treatment of MS.
Although, in some instances, radiation is used in combination with chemotherapy to treat MS.
However, no added advantage was observed in those cases [11, 38]. In addition, hematopoietic
stem cell transplantation is also used, albeit retrospectively, in MS patients [1]. Reported data
does suggest an advantage of auto- or allo-HSCT in MS patients with or without concomitant
AML irrespective of age, gender, anatomic location, clinical presentation or cytogenic status
[1, 3, 11]. In addition, retrospective chemotherapy trials conducted by the Children’s Cancer
Group demonstrated a better event-free survival for children with isolated MS than patients
with concurrent AML [38].
Taken together, however, no studies ever compared the different prognostic factors in MS
patients with or without AML and consequently, their effects on the treatment regimens. The
published data, nevertheless, do suggest a difference in prognosis between patients with
isolated MS and with concurrent or relapsed AML. Traditionally, the simultaneous expression
of MS at diagnosis of AML is considered as poor prognosis. However, there is evidence
contrary to this observation.
As stated above, till now there is no specific treatment for MS. Consequently, to a large extent
the treatment of MS depends on the site, volume as well as the timing of diagnosis of the
extramedullary tumor. Based on these factors, the clinicians determine the treatment plan by
employing singly chemotherapy, radiation therapy or bone marrow transplantation or in
combination. A detailed discussion of these different therapeutic regimens is discussed below.
9. Chemotherapy
Systemic chemotherapy is the primary choice of treatment for both isolated MS and MS with
simultaneous bone marrow involvement. This is largely due to the fact that even if there is no
primary bone marrow involvement, isolated or primary MS ultimately gives rise to AML in
majority of the cases [3, 39]. Consequently, the chemotherapy regimens for MS generally
follow the same protocol as AML. All these regimens mainly include cytarabine with
fludarabine, idarubicin, or both. In some instances, granulocyte colony-stimulating factor (G-
CSF), daunorubicin and cyclophosphamide are also used [32, 37, 40]. In particular, combina-
tion therapy with cytarabine and daunorubicin has been demonstrated to achieve complete
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remission in 65% of MS patients. In addition, chemotherapy has also shown to be effective in
attenuating AML development in isolated MS cases (71%) in both adult and pediatric popu-
lation [37, 41]. However, at present there is not enough data to identify a specific chemother-
apy plan that is beneficial for MS.
10. Radiotherapy
In some instance, radiation is also used as a part of the treatment plan for MS. However,
existing data does suggest that radiation alone may not be sufficient enough to completely
eradicate MS. Study conducted by Bakst et al. has demonstrated that patients with isolated MS
generally respond better to systemic chemotherapy compared to radiotherapy [39]. In addi-
tion, there is also no conclusive data demonstrating that radiotherapy in MS alone can prevent
the development of systemic leukemia involving bone marrow (40%). Consequently, in most
cases radiation is used in combination with chemotherapy in treating MS [42].
11. Bone marrow transplantation
Allo-SCT has also been demonstrated to be beneficial in treating isolated MS. Consequently,
many investigators/clinicians considered allo-SCT as a primary line treatment following
remission in MS patients [21, 43]. However, in a retrospective study, Chevallier et al. have
showed that there is no difference in 5-year survival rate in patients with isolated or MS
with leukemia when treated with allo-SCT [43]. In both the cases, the average survival was
48% for 5-year survival. In a different study, Pileri et al. showed that MS patients receiving
transplantation demonstrated a better overall survival rate (70%), than patients who did
not receive transplantation (0%) as a part of the treatment plan [21]. In subgroup analysis,
transplantation did not display any biasness depending on age, tumor site, timing of diag-
nosis etc. [21].
Taken together, these reports do suggest that transplantation should be considered as a part of
the consolidation therapy following remission in both isolated and leukemic MS in adult and
pediatric patients. However, one should be cautious as there are reports of manifestation of MS
postallo-SCT, most likely due to reduced graft-versus-leukemia (GVL) state at extramedullary
sites [25].
At present, there is not enough data in the field to make an informed choice for the best course
of treatment for different variants of MS. Based on the existing data, it is reasonable to consider
systemic chemotherapy as the best course of action, in association with radiotherapy and allo-
SCT depending on the bone marrow involvement. Given the fact that most of the reports are
isolated, single center analysis with small patient pool, it is not possible to develop a consensus
therapeutic regimen. To achieve such MS specific therapy, large multicenter collaboration and
development of prospective clinical trials is imperative.
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12. Targeted therapy: a possibility for the future?
Next-generation sequencing (NGS) and mutational analysis have uncovered significant
insights into the pathogenicity of leukemia. Consequently, the chances to develop targeted
therapies for leukemia have become a distinct possibility. However, due to misdiagnosis and
paucity of clinical samples, such comprehensive analysis for MS is still lacking. Nonetheless,
studies conducted with small cohorts of patients did report mutations in genes such as FLT3
andNPM1. Li et al. performed an NGS analysis with six patients with a custom panel targeting
21 common genes associated with AML and myelodysplastic syndrome (MDS) [44]. In addi-
tion to FLT3 and NPM1, the authors were also able to identify mutations in several genes such
as KIT, TET2, EZH2, SF3B1 and ASXL1 akin to AML [44]. This report does provide substantial
evidence of an underlying similarity in the pathogenicity between MS and AML. The impor-
tance of targeted therapy is further accentuated by Piccaluga and colleagues [45]. In this study,
the authors used an anti-CD33 monoclonal antibody to treat MS patients with concurrent
CD33-positive AML. Two out five patients in the study elicited a complete remission of both
MS and AML, while two patients showed reductions of extramedullary disease only [45]. In a
different study, treatment of MS patients with BCR-ABL1, FLT3-ITD and FIP1L1-PDGFRA
mutations by tyrosine kinase inhibitors (TKIs) also showed encouraging outcome [46].
Taken together these observations does suggest that akin to AML a similar sequencing (whole
genome, whole exome, and RNA seq.) base analysis should be employed in case of MS.
However, the success of such an endeavor depends on the obtainability of large cohorts of
samples, which unfortunately is a rarity in case of MS. Large multicenter collaboration is
essential to circumvent this problem.
13. Conclusion
Myeloid sarcoma is acknowledged as a separate disease entity for a significant period. It is an
extremely rare hematological malignancy and is often associated with poor prognosis. Due to
the scarcity of samples, there is no risk assessment study for MS. There are several unanswered
questions for MS. Specifically, is there a bias for certain AML (such as CBF leukemia) to induce
extramedullary infiltration. If yes, what is the primary mechanism(s) that drives the processes?
Does MS represent alternate molecular landscapes, clonal evolution, from the original bone
marrow disease? It can be argued that MS reflects a state of reduced immune surveillance in a
patient at diagnosis or following hematopoietic stem cell transplantation. Consequently, this
raises the possibility that MS may serve as a sanctuary site for leukemic relapse. The observa-
tion supports this implication that isolated MS ultimately gives rise to leukemia involving
bone marrow.
MS is often challenging to identify and even more challenging to diagnose. Owing to its
similarity with solid tumors, MS is often misdiagnosed, particularly as non-Hodgkin lym-
phoma. Accurate diagnosis of MS required an orchestrated approach involving whole body
imaging (PET/CT, MRI), broad panels of immunohistochemical staining, and FISH assay for
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cytogenetic and chromosomal abnormalities. Also, bone marrow biopsy should be that part of
the diagnosis. In fact, all isolated MS cases should be prophylactically treated for AML even if
there is no detectable leukemia. Caution should be exercised when analyzing immunohisto-
chemistry for MS. For example, CD43 and CD68, although, a reliable indicator of AML, should
be correlated with CD33, myeloperoxidase staining for accurate MS diagnosis. Treatment
should involve systemic chemotherapy as the first line of treatment with radiotherapy and
allo-HCT as part of the consolidation therapy. Surgery should be employed for tumor resec-
tion, if possible.
We need more prospective studies with larger patient cohorts to understand the mechanism(s)
of MS development. In addition, future studies should be directed to whole genome sequenc-
ing of MS samples to understand the different genetic abnormalities associated with MS and
how they differ from the corresponding bone marrow disease. Genetic information will also
help in better patient stratification. As evident from the whole-body PET/CT imaging, the
incidence of MS is more prevalent than expected indicating that we most likely have
underestimated the impact and implications of MS.
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